High levels of viral repression, malnutrition and second-line ART use in adolescents living with HIV: a mixed methods study from Myanmar.
Acquired Immunodeficiency Syndrome
/ drug therapy
Adolescent
Anti-HIV Agents
/ adverse effects
Body Mass Index
Caregivers
Child
Cohort Studies
Female
Focus Groups
Humans
Male
Malnutrition
/ epidemiology
Medication Adherence
Myanmar
/ epidemiology
Prevalence
Treatment Outcome
Viral Load
/ drug effects
Young Adult
ALHIV
Adherence
HIV/AIDS
Lipodystrophy
Qualitative
Teen clubs
Journal
BMC infectious diseases
ISSN: 1471-2334
Titre abrégé: BMC Infect Dis
Pays: England
ID NLM: 100968551
Informations de publication
Date de publication:
20 Mar 2020
20 Mar 2020
Historique:
received:
17
10
2019
accepted:
12
03
2020
entrez:
22
3
2020
pubmed:
22
3
2020
medline:
27
5
2020
Statut:
epublish
Résumé
Adolescents living with HIV/AIDS (ALHIV) are a particularly vulnerable but often overlooked group in the HIV response despite additional disease management challenges. All ALHIV (10-19 years), on ART for ≥6 months, presenting to care at a Médecins Sans Frontières (MSF) clinic in Myanmar from January-April 2016 were eligible for the quantitative study component (clinical history, medical examination, laboratory investigation). A subset of these respondents were invited to participate in qualitative interviews. Interviews and focus groups were also conducted with other key informants (care givers, clinicians). Of 177 ALHIV, 56% (100) were aged 9-13 years and 77 (44%) were 14-19. 49% (86) had been orphaned by one parent, and 19% (33) by both. 59% (104) were severely underweight (BMI < 16). 47% presented with advanced HIV (WHO stage III/IV). 93% were virally supressed (< 250 copies/mL). 38 (21%) of ALHIV were on a second-line ART after first-line virological failure. Qualitative interviewing highlighted factors limiting adherence and the central role that HIV counsellors play for both ALHIV patients and caregivers. Our study shows good clinical, immunological, and virological outcomes for a cohort of Myanmar adolescents living with HIV, despite a majority being severely underweight, presenting with Stage III or IV illness, and the prevalence of comorbid infections (TB). Many treatment and adherence challenges were articulated in qualitative interviewing but emphasized the importance of actively engaging adolescents in their treatment. Comprehensive HIV care for this population must include routine viral load testing and social support programs.
Sections du résumé
BACKGROUND
BACKGROUND
Adolescents living with HIV/AIDS (ALHIV) are a particularly vulnerable but often overlooked group in the HIV response despite additional disease management challenges.
METHODS
METHODS
All ALHIV (10-19 years), on ART for ≥6 months, presenting to care at a Médecins Sans Frontières (MSF) clinic in Myanmar from January-April 2016 were eligible for the quantitative study component (clinical history, medical examination, laboratory investigation). A subset of these respondents were invited to participate in qualitative interviews. Interviews and focus groups were also conducted with other key informants (care givers, clinicians).
RESULTS
RESULTS
Of 177 ALHIV, 56% (100) were aged 9-13 years and 77 (44%) were 14-19. 49% (86) had been orphaned by one parent, and 19% (33) by both. 59% (104) were severely underweight (BMI < 16). 47% presented with advanced HIV (WHO stage III/IV). 93% were virally supressed (< 250 copies/mL). 38 (21%) of ALHIV were on a second-line ART after first-line virological failure. Qualitative interviewing highlighted factors limiting adherence and the central role that HIV counsellors play for both ALHIV patients and caregivers.
CONCLUSIONS
CONCLUSIONS
Our study shows good clinical, immunological, and virological outcomes for a cohort of Myanmar adolescents living with HIV, despite a majority being severely underweight, presenting with Stage III or IV illness, and the prevalence of comorbid infections (TB). Many treatment and adherence challenges were articulated in qualitative interviewing but emphasized the importance of actively engaging adolescents in their treatment. Comprehensive HIV care for this population must include routine viral load testing and social support programs.
Identifiants
pubmed: 32197588
doi: 10.1186/s12879-020-04968-x
pii: 10.1186/s12879-020-04968-x
pmc: PMC7085147
doi:
Substances chimiques
Anti-HIV Agents
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
241Références
Lancet. 2004 Jan 10;363(9403):157-63
pubmed: 14726171
Global Health. 2017 Sep 12;13(1):72
pubmed: 28899415
AIDS. 2015 Jul 31;29(12):1527-36
pubmed: 26244392
Clin Infect Dis. 2018 Mar 4;66(suppl_2):S103-SS105
pubmed: 29514231
AIDS. 2013 Mar 13;27(5):781-5
pubmed: 23169331
J Int AIDS Soc. 2012 Jul 02;15(2):17427
pubmed: 22814353
J Acquir Immune Defic Syndr. 2014 Jul 1;66 Suppl 2:S144-53
pubmed: 24918590
Glob Health Action. 2017;10(1):1290916
pubmed: 28594295
J Int AIDS Soc. 2017 May 16;20(Suppl 3):21591
pubmed: 28530038
PLoS One. 2016 Dec 8;11(12):e0168057
pubmed: 27930740
AIDS. 2014 Aug 24;28(13):1945-56
pubmed: 24845154
PLoS One. 2015 Feb 19;10(2):e0116144
pubmed: 25695494
Pediatr Infect Dis J. 2015 Mar;34(3):e63-70
pubmed: 25742090
Pediatr Infect Dis J. 2014 Mar;33(3):291-4
pubmed: 23942457
J Int AIDS Soc. 2017 May 16;20(Suppl 3):21520
pubmed: 28530036
PLoS One. 2017 Feb 9;12(2):e0171780
pubmed: 28182786
Clin Infect Dis. 2010 Jul 15;51(2):214-24
pubmed: 20536367